Hives News and Research RSS Feed - Hives News and Research

Hives (or Urticaria) are a kind of skin rash notable for dark red, raised, itchy bumps. Hives are frequently caused by allergic reactions; however, there are many non-allergic causes.
Food-triggered atopic dermatitis in children may lead to life-threatening anaphylaxis risk

Food-triggered atopic dermatitis in children may lead to life-threatening anaphylaxis risk

Elimination of the food that triggers atopic dermatitis, or eczema, is associated with increased risk of developing immediate reactions to that food, according to the results of a large-scale study recently published in the Journal of Allergy and Clinical Immunology. [More]
Common misconception about penicillin allergies

Common misconception about penicillin allergies

It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was your parents who said so. According to a Texas A&M Health Science Center allergist, many people who believe they're allergic to this antibiotic may not actually be allergic at all. [More]
Researchers observe worrisome increase in anaphylaxis rate

Researchers observe worrisome increase in anaphylaxis rate

Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre. [More]
Vanderbilt's A.S.A.P sees increase in number of patients treated for alpha-gal syndrome

Vanderbilt's A.S.A.P sees increase in number of patients treated for alpha-gal syndrome

Vanderbilt's Asthma, Sinus and Allergy Program (A.S.A.P) has seen an increase in the number of patients being treated for alpha-gal syndrome, commonly known as the red meat allergy linked to tick bites. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
NIH researchers identify genetic mutation responsible for vibratory urticaria

NIH researchers identify genetic mutation responsible for vibratory urticaria

Scientists at the National Institutes of Health have identified a genetic mutation responsible for a rare form of inherited hives induced by vibration, also known as vibratory urticaria. Running, hand clapping, towel drying or even taking a bumpy bus ride can cause temporary skin rashes in people with this rare disorder. [More]
Simple method to purify cashew allergens could help scientists better understand allergic reactions

Simple method to purify cashew allergens could help scientists better understand allergic reactions

It's well known that peanuts can cause severe reactions in people who are allergic, but research suggests that the risk of developing a life-threatening reaction could be higher for those allergic to cashews. Now scientists have come up with a fast and simple method to purify the three main cashew allergens to help better grasp how they work and their effects on people. [More]
American Academy of Dermatology releases Chronic Hives Patient App

American Academy of Dermatology releases Chronic Hives Patient App

Patients who are struggling with chronic hives can turn to a new free tool for help. This month, the American Academy of Dermatology released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. [More]
Majority of people not allergic to intravenous penicillins, say ACAAI allergists

Majority of people not allergic to intravenous penicillins, say ACAAI allergists

Most people who think they're allergic to penicillin have been told so by a doctor after they've had a reaction to the drug. And the majority, even though they've never been allergy tested, never take penicillin again. [More]
New research shows siblings of children with food allergies have sensitivity, but not true allergy

New research shows siblings of children with food allergies have sensitivity, but not true allergy

If one child in a family has a food allergy, the reasoning sometimes goes, chances are good that siblings might also have food allergies. Not necessarily, according to new research which shows that 53 percent of siblings of children with food allergies had a food sensitivity, but only 13 percent had actual food allergy. [More]
Nucala (mepolizumab) approved for treatment of asthma patients

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [More]
Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD. [More]
Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States. [More]
Repatha (evolocumab) injection gets FDA approval for high cholesterol

Repatha (evolocumab) injection gets FDA approval for high cholesterol

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. [More]
FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg. [More]
Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation. [More]
Shire enters into agreement with Sanquin for CINRYZE

Shire enters into agreement with Sanquin for CINRYZE

Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE. [More]
EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. [More]
New research reveals why some kids can have severe allergic reaction hours later

New research reveals why some kids can have severe allergic reaction hours later

Parents of kids with severe allergies know how scary a severe allergic reaction (anaphylaxis) is. New research offers clues as to why some kids can have a second, related reaction hours later - and what to do about it. [More]
Advertisement